
## Susan E Creary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4660386/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Advances, 2020, 4, 2656-2701.	5.2	184
2	A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickleâ€cell disease. Pediatric Blood and Cancer, 2014, 61, 1068-1073.	1.5	62
3	Losartan for the nephropathy of sickle cell anemia: A phaseâ€2, multicenter trial. American Journal of Hematology, 2017, 92, E520-E528.	4.1	36
4	Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Advances, 2018, 2, 285-291.	5.2	32
5	Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. Blood Advances, 2020, 4, 1501-1511.	5.2	28
6	Desire for parenthood and reproductive health knowledge in adolescents and young adults with sickle cell disease and their caregivers. Pediatric Blood and Cancer, 2018, 65, e26829.	1.5	26
7	Sickle cell trait knowledge and health literacy in caregivers who receive in-person sickle cell trait education. Molecular Genetics & Genomic Medicine, 2017, 5, 692-699.	1.2	22
8	Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study. Journal of Pediatrics, 2018, 197, 186-190.e1.	1.8	19
9	Identification of Unique, Heterozygous Germline Mutation, <i>STK11</i> (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma. Pediatric and Developmental Pathology, 2015, 18, 318-323.	1.0	16
10	A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. JMIR MHealth and UHealth, 2019, 7, e13452.	3.7	16
11	Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Research Notes, 2015, 8, 372.	1.4	14
12	ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease. JMIR Research Protocols, 2016, 5, e193.	1.0	14
13	Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research. International Journal of Environmental Research and Public Health, 2016, 13, 1131.	2.6	12
14	Diverse manifestations of acute sickle cell hepatopathy in pediatric patients with sickle cell disease: A case series. Pediatric Blood and Cancer, 2018, 65, e27060.	1.5	12
15	Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?. Pediatric Blood and Cancer, 2016, 63, 844-847.	1.5	11
16	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Trials, 2020, 21, 983.	1.6	11
17	A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia. Blood, 2016, 128, 265-265.	1.4	10
18	Prodromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, 480-483.	0.6	9

SUSAN E CREARY

#	Article	IF	CITATIONS
19	Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28250.	1.5	8
20	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
21	Fertility Testing Knowledge and Attitudes in Male Adolescents and Young Adults with SCD and Their Caregivers: A Pilot Study. Blood Advances, 2022, , .	5.2	8
22	A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring. Pediatric Quality & Safety, 2017, 2, e024.	0.8	6
23	Telehealth Use Before and During the COVID-19 Pandemic Among Children with Sickle Cell Anemia. Telemedicine Journal and E-Health, 2022, 28, 1166-1171.	2.8	6
24	Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease. Journal of Pediatric Psychology, 2019, 44, 1196-1204.	2.1	5
25	A health literate approach to address health disparities: a virtual program for parents of children with sickle cell trait. Journal of Communication in Healthcare, 2022, 15, 112-120.	1.5	5
26	Baseline and Disease-Induced Transcriptional Profiles in Children with Sickle Cell Disease. Scientific Reports, 2020, 10, 9013.	3.3	4
27	Trends in quality of care among children with sickle cell anemia. Pediatric Blood and Cancer, 2022, 69, e29446.	1.5	4
28	Thrombocytopenia Pitfalls: Misdiagnosing Type 2B von Willebrand Disease as Ethylenediaminetetraacetic Acidâ `Dependent Pseudothrombocytopenia. Journal of Pediatrics, 2016, 175, 238-238.e1.	1.8	3
29	Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatric Blood and Cancer, 2018, 66, e27588.	1.5	3
30	Opioid Prescription Filling Trends Among Children with Sickle Cell Disease After the Release of State-Issued Guidelines on Pain Management. Pain Medicine, 2020, 21, 2583-2592.	1.9	3
31	Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia. Pediatric Blood and Cancer, 2022, , e29607.	1.5	3
32	Influenza immunization coverage of children with sickle cell disease. Vaccine, 2021, 39, 5538-5540.	3.8	2
33	Acceptability to and Engagement With a Virtual Sickle Cell Trait Education Program (SCTaware): Single-Center Prospective Study. JMIR Formative Research, 2022, 6, e38780.	1.4	2
34	A pilot study of hormonal contraceptive use and bone mineral density in young women with sickle cell disease. Pediatric Blood and Cancer, 2018, 65, e27398.	1.5	0
35	Upper airway microbiome changes in children with sickle cell disease during vasoâ€occlusive and acute chest syndrome episodes. American Journal of Hematology, 2020, 95, E289.	4.1	0
36	Primary Immunization Series Coverage of Children With Sickle Cell Disease. American Journal of Preventive Medicine, 2021, 61, 124-127.	3.0	0

#	Article	IF	CITATIONS
37	Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease. Blood, 2020, 136, 26-27.	1.4	0